have to say the market cap seems very low for a company this far down the lie in developing a unique technology that will help revolutionise the diagnosis and treatment of asthma.
the hard work has all been done in research and development. sales will not be a straight line to success, but they certainly appear to know whats required (ie: getting the insurance companies and doctors on side)
with market cap of $12m it's easy to see it getting closer to $50m without breaking a sweat at the first sign that the the business plan is bearing fruit.
KSX Price at posting:
2.4¢ Sentiment: Buy Disclosure: Held
